Date: 2016-12-02
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Acetylon Pharmaceuticals (USA - MA) Regenacy Pharmaceuticals (USA - MA)
Therapeutic area: CNS diseases - Rare diseases - Genetic diseases - Hematological diseases
Type agreement:
Action mechanism:
Disease: diabetic neuropathy, sickle cell disease, beta-thalassemia
Details: * On December 2, 2016, Acetylon Pharmaceuticals announced that it has entered into an agreement to be acquired by Celgene Corporation. Prior to the consummation of the acquisition, Acetylon will spin out a new company, Regenacy Pharmaceuticals, which will focus on the development of novel drug candidates that selectively regenerate intracellular transport and upregulate gene expression to modify the course of disease. Regenacy will receive exclusive worldwide rights to Acetylon’s Phase 2 selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat (ACY-1215), for the treatment of certain non-cancer disease indications including neuropathies, as well as Acetylon’s preclinical selective HDAC1,2 inhibitor candidates and patent families for development in all human disease indications including sickle cell disease and beta-thalassemia.
Regenacy’s programs will selectively inhibit histone deacetylase 6 (HDAC6) to restore normal protein and organelle intracellular transport in diabetic and other peripheral neuropathies and inhibit HDACs 1 and 2 to restore oxygen transport in orphan blood disorders such as sickle cell disease and beta-thalassemia, regenerate normal cognitive function in patients with psychiatric disorders, and restore normal white blood cell function in acute myeloid leukemia (AML).
Financial terms:
Latest news:
